annual EBITDA:
-$380.21M-$6.06M(-1.62%)Summary
- As of today (August 29, 2025), RLAY annual EBITDA is -$380.21 million, with the most recent change of -$6.06 million (-1.62%) on December 31, 2024.
- During the last 3 years, RLAY annual EBITDA has fallen by -$157.13 million (-70.44%).
- RLAY annual EBITDA is now -696.50% below its all-time high of -$47.73 million, reached on December 31, 2018.
Performance
RLAY EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly EBITDA:
-$75.84M+$7.82M(+9.34%)Summary
- As of today (August 29, 2025), RLAY quarterly EBITDA is -$75.84 million, with the most recent change of +$7.82 million (+9.34%) on June 30, 2025.
- Over the past year, RLAY quarterly EBITDA has increased by +$34.92 million (+31.52%).
- RLAY quarterly EBITDA is now -311.27% below its all-time high of $35.90 million, reached on December 31, 2020.
Performance
RLAY quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBITDA:
-$338.15M+$34.92M(+9.36%)Summary
- As of today (August 29, 2025), RLAY TTM EBITDA is -$338.15 million, with the most recent change of +$34.92 million (+9.36%) on June 30, 2025.
- Over the past year, RLAY TTM EBITDA has increased by +$29.71 million (+8.08%).
- RLAY TTM EBITDA is now -2049.05% below its all-time high of -$15.73 million, reached on March 31, 2019.
Performance
RLAY TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
RLAY EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -1.6% | +31.5% | +8.1% |
| 3 y3 years | -70.4% | +1.1% | -26.7% |
| 5 y5 years | -368.2% | -182.4% | -242.6% |
RLAY EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -70.4% | at low | -3.3% | +31.5% | -26.7% | +13.2% |
| 5 y | 5-year | -627.7% | at low | -311.3% | +31.5% | -547.2% | +13.2% |
| alltime | all time | -696.5% | at low | -311.3% | +31.5% | -2049.1% | +13.2% |
RLAY EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2025 | - | -$75.84M(-9.3%) | -$338.15M(-9.4%) |
| Mar 2025 | - | -$83.66M(+0.0%) | -$373.07M(-1.9%) |
| Dec 2024 | -$380.21M(+1.6%) | -$83.64M(-12.0%) | -$380.21M(-2.4%) |
| Sep 2024 | - | -$95.00M(-14.2%) | -$389.45M(+5.9%) |
| Jun 2024 | - | -$110.76M(+22.0%) | -$367.87M(+1.1%) |
| Mar 2024 | - | -$90.80M(-2.2%) | -$363.97M(-2.7%) |
| Dec 2023 | -$374.15M(+21.9%) | -$92.89M(+26.5%) | -$374.15M(+2.9%) |
| Sep 2023 | - | -$73.41M(-31.3%) | -$363.49M(-2.2%) |
| Jun 2023 | - | -$106.87M(+5.8%) | -$371.68M(+8.8%) |
| Mar 2023 | - | -$100.98M(+22.8%) | -$341.46M(+11.3%) |
| Dec 2022 | -$306.82M | -$82.23M(+0.8%) | -$306.82M(+5.6%) |
| Sep 2022 | - | -$81.60M(+6.4%) | -$290.45M(+8.9%) |
| Jun 2022 | - | -$76.66M(+15.5%) | -$266.83M(+7.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2022 | - | -$66.34M(+0.7%) | -$247.94M(+11.1%) |
| Dec 2021 | -$223.08M(+327.0%) | -$65.85M(+13.6%) | -$223.08M(+83.9%) |
| Sep 2021 | - | -$57.98M(+0.4%) | -$121.33M(+22.5%) |
| Jun 2021 | - | -$57.77M(+39.2%) | -$99.05M(+45.4%) |
| Mar 2021 | - | -$41.49M(-215.6%) | -$68.13M(+30.4%) |
| Dec 2020 | -$52.25M(-35.7%) | $35.90M(-200.6%) | -$52.25M(-53.8%) |
| Sep 2020 | - | -$35.69M(+32.9%) | -$113.13M(+14.6%) |
| Jun 2020 | - | -$26.85M(+4.9%) | -$98.71M(+8.4%) |
| Mar 2020 | - | -$25.60M(+2.5%) | -$91.07M(+12.1%) |
| Dec 2019 | -$81.20M(+70.1%) | -$24.98M(+17.4%) | -$81.20M(+44.4%) |
| Sep 2019 | - | -$21.27M(+10.7%) | -$56.22M(+60.9%) |
| Jun 2019 | - | -$19.21M(+22.1%) | -$34.95M(+122.1%) |
| Mar 2019 | - | -$15.73M | -$15.73M |
| Dec 2018 | -$47.73M | - | - |
FAQ
- What is Relay Therapeutics, Inc. annual EBITDA?
- What is the all time high annual EBITDA for Relay Therapeutics, Inc.?
- What is Relay Therapeutics, Inc. annual EBITDA year-on-year change?
- What is Relay Therapeutics, Inc. quarterly EBITDA?
- What is the all time high quarterly EBITDA for Relay Therapeutics, Inc.?
- What is Relay Therapeutics, Inc. quarterly EBITDA year-on-year change?
- What is Relay Therapeutics, Inc. TTM EBITDA?
- What is the all time high TTM EBITDA for Relay Therapeutics, Inc.?
- What is Relay Therapeutics, Inc. TTM EBITDA year-on-year change?
What is Relay Therapeutics, Inc. annual EBITDA?
The current annual EBITDA of RLAY is -$380.21M
What is the all time high annual EBITDA for Relay Therapeutics, Inc.?
Relay Therapeutics, Inc. all-time high annual EBITDA is -$47.73M
What is Relay Therapeutics, Inc. annual EBITDA year-on-year change?
Over the past year, RLAY annual EBITDA has changed by -$6.06M (-1.62%)
What is Relay Therapeutics, Inc. quarterly EBITDA?
The current quarterly EBITDA of RLAY is -$75.84M
What is the all time high quarterly EBITDA for Relay Therapeutics, Inc.?
Relay Therapeutics, Inc. all-time high quarterly EBITDA is $35.90M
What is Relay Therapeutics, Inc. quarterly EBITDA year-on-year change?
Over the past year, RLAY quarterly EBITDA has changed by +$34.92M (+31.52%)
What is Relay Therapeutics, Inc. TTM EBITDA?
The current TTM EBITDA of RLAY is -$338.15M
What is the all time high TTM EBITDA for Relay Therapeutics, Inc.?
Relay Therapeutics, Inc. all-time high TTM EBITDA is -$15.73M
What is Relay Therapeutics, Inc. TTM EBITDA year-on-year change?
Over the past year, RLAY TTM EBITDA has changed by +$29.71M (+8.08%)